You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
福安藥業(300194.SZ):多索茶鹼注射液通過仿製藥一致性評價
格隆匯 06-18 17:52

格隆匯6月18日丨福安藥業(300194.SZ)公佈,公司全資子公司福安藥業集寧波天衡製藥有限公司(“天衡藥業”)於近日收到國家藥品監督管理局核准簽發的藥品補充申請批准通知書,其產品多索茶鹼注射液通過了仿製藥質量和療效一致性評價。

多索茶鹼注射液主要適用於支氣管哮喘、喘息性慢性支氣管炎及其他支氣管痙攣引起的呼吸困難。

多索茶鹼注射液通過一致性評價將進一步提升公司該產品的技術水平,有利於提高產品的市場競爭力。但該產品未來生產和銷售可能受市場、政策等因素的影響,具體經營情況具有不確定性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account